Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

Affiliations

• 1 University of Groningen, Groningen, The Netherlands.
• 2 MyoKardia, Brisbane, CA, USA.
• 3 Robertson Centre for Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.
• 4 Jacksonville Center for Clinical Research, Jacksonville, FL, USA.
• 5 HealthEast Heart Care, Saint Paul, MN, USA.
• 6 Tennova Healthcare-Harton, Tullahoma, TN, USA.
• 7 Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
• 8 Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden.
• 9 Oregon Health & Science University, Portland, OR, USA.
• 10 Department of Medicine, Duke University Medical Center, Durham, NC, USA.
• 11 Antonius Ziekenhuis Sneek, Sneek, The Netherlands.
• 12 Charité Research Organization, Berlin, Germany.
• 13 Divisions of Human Genetics and Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA.
• 14 Cardiovascular Imaging Core Laboratory, Brigham and Women's Hospital, Boston, MA, USA.
• 15 Teichman Drug Development Consulting, Oakland, CA, USA.
• 16 Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.